The number of women who've told me they assumed their irregular cycles meant 'job done, no more contraception needed' — and then found themselves staring at a positive test in their mid-40s — is not small. This one sits close to my heart because the silence around perimenopausal fertility is so loud, and the consequences of getting it wrong fall entirely on women.
Learn more about Rose →Irregular cycles in perimenopause reflect disrupted follicle recruitment and erratic estrogen surges — but ovulation can and does still occur, often unpredictably. A cycle that is longer, shorter, or skipped entirely does not confirm that no egg was released that month. In fact, some perimenopausal cycles involve perfectly normal ovulation sandwiched between cycles that do not — making pattern-reading an unreliable contraceptive strategy.
Natural conception rates do fall significantly after 40, but they do not reach zero until menopause is confirmed — and even then, the transition period matters. Studies consistently show that women in their early-to-mid 40s retain a meaningful, if reduced, chance of natural conception per cycle. Unintended pregnancy rates in the 40–44 age group remain high enough that reproductive health organizations across the UK, US, and Australia all recommend continued contraception use throughout perimenopause.
FSH levels in perimenopause are notoriously variable — a high reading one month can be followed by a normal reading the next, because FSH fluctuates dramatically as the pituitary attempts to recruit failing follicles. No single FSH test, no matter how elevated, can confirm permanent infertility or replace a confirmed 12-month absence of periods as the standard for menopause. Relying on a single blood test to make contraceptive decisions is one of the most common and consequential errors women in their 40s make.
The internationally accepted clinical threshold for confirmed menopause — and therefore the point at which contraception can be safely discontinued — is 12 consecutive months without a period for women over 50, and 24 consecutive months for women under 50. A six-month gap in periods is common in perimenopause and does not indicate permanent cessation of ovarian function. Women who stop contraception at six months are still within a window where ovulation and conception remain biologically possible.
While it is true that the combined oral contraceptive pill can suppress some perimenopausal symptoms and make cycle tracking unreliable, this is not true of all hormonal contraception. A progestogen-only method or a hormonal IUD, for example, can provide effective contraception without substantially altering the hormonal landscape in ways that hide perimenopause. Understanding which method is being used — and why — allows women and their clinicians to make decisions that protect fertility goals and symptom awareness simultaneously.
This is a critical and surprisingly widespread misunderstanding. MHT — whether patches, gels, sprays, or systemic tablets — is not a contraceptive. It does not suppress ovulation and was never designed to. Women who are using MHT to manage perimenopausal symptoms and who have not yet met the confirmed menopause threshold still require a separate, evidence-based contraceptive method if pregnancy prevention is the goal.
It is accurate that miscarriage rates increase significantly with age — rising to roughly 50% or higher in women over 45 — but that still leaves a substantial proportion of pregnancies that do not miscarry. Continuing to rely on high miscarriage rates as a de facto contraceptive strategy is not evidence-based and can lead to outcomes that are medically, emotionally, and practically significant. The risks of pregnancy itself — including chromosomal abnormalities and obstetric complications — also increase with age, making the stakes of an unintended pregnancy higher, not lower.
Emergency contraception efficacy is primarily tied to body weight and timing of use, not age. There is no evidence that levonorgestrel-based emergency contraception becomes less effective simply because a woman is in her 40s. What does matter is that it is taken as quickly as possible after unprotected sex, and that women with higher body weight may need to discuss the copper IUD as a more reliable emergency option with a healthcare provider.
Blanket avoidance of the combined oral contraceptive pill in all women over 40 is not current evidence-based guidance. Risk is individual and depends heavily on factors including smoking status, BMI, blood pressure, personal and family cardiovascular history, and migraine history. For healthy non-smoking women in their early 40s without contraindications, combined hormonal contraception can remain a clinically appropriate option — and the Faculty of Sexual and Reproductive Healthcare (FSRH) guidelines reflect this nuance rather than an age-based cut-off.
The copper IUD is highly effective and hormone-free, making it a popular choice in perimenopause — but timing of removal matters. If a copper IUD is fitted after age 40, current FSRH guidance suggests it can remain in place until menopause is confirmed, providing ongoing contraception without replacement. However, a woman who had hers fitted before 40 may need a replacement depending on the device's licensed duration, and assuming ongoing protection without checking the insertion date is a practical error worth avoiding.
Understanding perimenopausal fertility biology matters even for women who have completed their families or who are not in relationships where pregnancy is possible — because the same hormonal signals that govern ovulatory unpredictability are deeply connected to symptom patterns, bone health, cardiovascular risk timing, and decisions about when to start MHT. Knowing where a woman sits in the fertility transition helps clinicians time hormone therapy appropriately and helps women understand their bodies during a phase that is too often treated as a blank space between reproductive life and old age.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.